Skip to content
Clinical Trials – home

Combined immunodeficiency Diagnostics

1 / 1 trials open to patients1 country

In short

Diagnosing combined immunodeficiency is a crucial step toward protecting children who are born with a weakened immune system. Early detection through screening and specialized blood tests can help doctors identify the problem before severe infections occur, improving the chances of successful treatment and a healthier future.

Key points

  • Combined immunodeficiency affects both T cells and B cells, making children vulnerable to a wide range of infections and immune system complications.
  • Early diagnosis through blood tests and genetic testing is crucial for determining the best treatment approach and improving outcomes.
  • Children who show repeated or severe infections, chronic diarrhea, or failure to thrive should be evaluated by a specialist in immune system disorders.
  • Complete blood counts and specialized lymphocyte function tests are the foundation of CID diagnosis, though genetic testing provides the definitive confirmation.
  • Clinical trials for new treatments require thorough diagnostic testing to ensure children meet specific criteria and are appropriate candidates for experimental therapies.
  • The success rate of bone marrow transplantation for combined immunodeficiency has improved dramatically, reaching around ninety percent in some cases when performed early.
  • Some children with milder forms of CID may not show symptoms until later in childhood, making ongoing monitoring and awareness of warning signs important.

Introduction: Who Should Undergo Diagnostics

Combined immunodeficiency, often shortened to CID, is a group of rare genetic disorders where both main types of infection-fighting cells in the body—called T cells and B cells—are either too few in number or do not work properly. These cells are part of what is known as the adaptive immune system, which learns to recognize and fight off specific germs like bacteria, viruses, fungi, and parasites. When this system is weakened, even common infections that most people easily shake off can become serious or life-threatening.

Children with combined immunodeficiency often show signs of illness within the first two years of life. The most common warning signs include repeated infections that keep coming back, infections that do not respond well to treatment, or infections that are unusually severe. Some children may also experience problems with their immune system going into overdrive, causing inflammation or autoimmune conditions where the body mistakenly attacks its own tissues. This happens because the immune cells are present but do not function correctly, leading to what doctors call immune dysregulation.

Parents and caregivers should seek medical evaluation if their child has frequent or severe respiratory infections, chronic diarrhea that does not improve, skin rashes that persist, or fails to gain weight at a normal rate. These symptoms, especially when they occur repeatedly or do not improve with standard treatments, may suggest an underlying immune system problem. It is important to remember that some children with milder forms of CID may not show symptoms until later in childhood or even early adulthood, making it harder to detect the condition early.

Diagnostic Methods for Combined Immunodeficiency

Diagnosing combined immunodeficiency requires a combination of careful observation, detailed medical history, and specialized laboratory tests. Doctors begin by reviewing the child's history of infections, including how often they occur, what types of germs cause them, and how the child responds to treatment. A physical examination is also important, as it can reveal specific findings associated with different forms of CID, such as skin rashes, poor growth, or signs of chronic inflammation.

The cornerstone of diagnosing CID is blood testing. A simple but essential test is the complete blood count, which measures the number of different types of blood cells, including white blood cells. Doctors pay close attention to the levels of lymphocytes, which are the white blood cells that include T cells and B cells. In combined immunodeficiency, the number of lymphocytes may be low, or they may be present but not functioning properly. The complete blood count can provide early clues that something is wrong with the immune system.

Beyond the basic blood count, doctors order more specialized tests to understand exactly which parts of the immune system are affected. These tests measure the specific numbers of T cells and B cells, as well as their ability to respond to challenges. For example, doctors may test whether B cells are making antibodies, which are proteins that target and destroy specific germs. They may also test how well T cells can activate and multiply when exposed to substances that should trigger an immune response. These functional tests help distinguish CID from other immune problems and identify the specific type of combined immunodeficiency a child has.

Another important part of the diagnostic process is genetic testing. Because combined immunodeficiency is caused by changes or mutations in specific genes, identifying the exact genetic variant can confirm the diagnosis and provide information about what to expect in terms of disease severity and progression. There are many different genetic variants that can cause CID, and each one affects the immune system in a slightly different way. Genetic testing can take weeks or months to complete, so doctors often start treatment based on clinical findings and blood tests while waiting for the genetic results.

Doctors may also use imaging tests or other procedures to check for complications of CID. For example, chest X-rays or CT scans can help identify lung infections or damage from repeated respiratory illnesses. In some cases, a biopsy of lymph nodes or other tissues may be needed to rule out other conditions or to understand the extent of immune system damage. However, these tests are not always necessary and depend on the individual child's symptoms and medical history.

It is important to note that the diagnosis of combined immunodeficiency is not always straightforward. Some children with milder forms of CID may have normal or near-normal lymphocyte counts, making it harder to detect the problem through routine blood tests. In these cases, functional tests that measure how well the immune cells work become even more important. Doctors may also repeat tests over time to look for patterns or trends, especially if the child's condition is borderline or unclear.

Diagnostics for Clinical Trial Qualification

When families consider enrolling their child in a clinical trial to test new treatments for combined immunodeficiency, additional diagnostic tests are often required. Clinical trials are research studies designed to find out whether a new treatment is safe and effective, and they have strict criteria for who can participate. These criteria, called inclusion and exclusion criteria, help ensure that the trial results are reliable and that participants are appropriate candidates for the experimental treatment being tested.

For combined immunodeficiency trials, doctors typically require a confirmed diagnosis through blood tests showing low or abnormal T cell and B cell function. Genetic testing is often necessary to identify the specific gene mutation causing the condition, as some trials are designed for specific genetic types of CID. For example, a trial testing a new gene therapy might only accept children with a particular genetic variant that the therapy is designed to correct.

Clinical trials may also require baseline measurements of the child's immune system before starting the experimental treatment. This includes detailed counts of different types of lymphocytes, measurements of antibody levels, and tests of how well the immune cells respond to stimulation. These baseline measurements help researchers track whether the treatment is having an effect and whether the child's immune system is improving over time. Without accurate baseline data, it would be difficult to determine if the treatment is working.

In addition to immune system tests, clinical trials often require general health assessments to make sure the child is healthy enough to participate. This may include tests of liver and kidney function, heart function, and overall nutritional status. Doctors may also check for active infections that need to be treated before starting the trial, as some experimental treatments could make infections worse if they are not controlled first.

Some trials may have age restrictions or require that the child be at a certain stage of the disease. For example, a trial might only accept children who have not yet received a bone marrow transplant, or it might focus on children with very severe forms of CID who have already tried other treatments without success. These requirements are designed to create a consistent group of participants so that researchers can accurately measure the treatment's effects.

⚠️ Important Clinical trials may offer access to cutting-edge treatments that are not yet widely available, but they also require careful consideration and thorough diagnostic testing to ensure your child is a good fit. Talk to your child's doctor about whether a clinical trial might be an option and what tests would be needed to qualify.

Prognosis and Survival Rate

Prognosis

The outlook for children with combined immunodeficiency depends on several factors, including how quickly the condition is diagnosed, the severity of the immune deficiency, the specific genetic cause, and whether the child receives appropriate treatment. Children with milder forms of CID who are diagnosed early and receive proper supportive care, such as immunoglobulin replacement therapy and preventive antibiotics, may have a better quality of life and fewer serious complications. However, predicting the exact course of the disease for an individual child can be challenging because the clinical spectrum of CID is wide, ranging from mild to severe.

Without definitive treatment, children with more severe forms of combined immunodeficiency face significant risks from repeated and serious infections. These infections can lead to long-term damage to organs such as the lungs, liver, and digestive system. In addition, some children may develop complications from immune dysregulation, including autoimmune diseases where the body attacks its own tissues, or inflammatory conditions that cause ongoing health problems. The prognosis is significantly better for children who receive early definitive therapy, particularly hematopoietic stem cell transplantation (HSCT), which has shown substantial success rates when performed early in life and especially when a well-matched donor is available.

Survival rate

The survival rate for combined immunodeficiency has improved dramatically in recent years due to advances in early diagnosis and treatment. The success rate of bone marrow or stem cell transplantation for CID is around ninety percent in some case series, particularly when an HLA-matched sibling donor is available. This represents a major improvement compared to the past when these conditions were often fatal in early childhood. Early intervention and the availability of better transplantation techniques, including the use of unrelated or partially matched donors, have made it possible for more children to survive and lead healthy lives.

Did you know?

  1. Combined immunodeficiency is different from severe combined immunodeficiency (SCID) because T cells are usually detectable in CID, though their function may be impaired, whereas in SCID, T cells are virtually absent.
  2. The success rate of bone marrow transplantation for immunodeficiency disorders has improved so much that it has become an acceptable treatment option even for children with less severe forms of CID.
  3. Some children with combined immunodeficiency may not show symptoms until later in childhood or early adulthood, making early diagnosis challenging without specialized testing.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Combined immunodeficiency

Recruiting trials first

See all 1 trials →
Quick filters

1 clinical trial in this condition

Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Containing The Human Dclre1C Gene
  • Sponsor:Assistance Publique Hopitaux De Paris
See all 1 trials →filters applied: condition = Combined immunodeficiency

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).